Quantitative systems pharmacology can reduce attrition and improve productivity in pharmaceutical research and development

Frontiers in Pharmacology

Volumn 5, Issue NOV, 2014, Pages

  Leil, Tarek A ^a   Bertz, Richard ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Drug discovery and development; Modeling and simulation; Pharmaceutical R D; Pharmacometrics; Quantitative systems pharmacology; Systems biology

Indexed keywords

ARTICLE; COMPUTER MODEL; COMPUTER SIMULATION; DECISION SUPPORT SYSTEM; DRUG APPROVAL; DRUG DEVELOPMENT; MEDICAL RESEARCH; METHODOLOGY; PHARMACEUTICAL RESEARCH AND DEVELOPMENT; PROCESS DEVELOPMENT; PROCESS MODEL; QUANTITATIVE SYSTEMS PHARMACOLOGY; SYSTEM ANALYSIS;

EID: 84926673199     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00247     Document Type: Article

References (22)

1. Agoram, B. M., and Demin, O. (2011). Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. Drug Discov. Today 16, 1031-1036. doi: 10.1016/j.drudis.2011.10.001
2. de Pasquale, A. (1984). Pharmacognosy: the oldest modern science. J. Ethnopharmacol. 11, 1-16. doi: 10.1016/0378-8741(84)90092-8
3. DiMasi, J. A., and Grabowski, H. (2007). The cost of biopharmaceutical R&D: is biotech different? MDE Manage. Decis. Econ. 28, 469-479. doi: 10.1002/mde.1360
4. Drews, J. (2000). Drug discovery: a historical perspective. Science 287, 1960-1964. doi: 10.1126/science.287.5460.1960
5. Edginton, A. N., Theil, F. P., Schmitt, W., and Willmann, S. (2008). Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin. Drug Metab. Toxicol. 4, 1143-1152. doi: 10.1517/17425255.4.9.1143
6. Eissing, T., Kuepfer, L., Becker, C., Block, M., Coboeken, K., Gaub, T., et al. (2011). A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front. Physiol. 2:4. doi: 10.3389/fphys.2011.00004
7. Geerts, H., Roberts, P., and Spiros, A. (2013a). A quantitative system pharmacology computer model for cognitive deficits in schizophrenia. CPT Pharmacometrics Syst. Pharmacol. 2:e36. doi: 10.1038/psp.2013.12
8. Geerts, H., Roberts, P., Spiros, A., and Carr, R. (2013b). A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer's disease. Front. Pharmacol. 4:47. doi: 10.3389/fphar.2013.00047
9. Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., and Rostami-Hodjegan, A. (2009). The Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 5, 211-223. doi: 10.1517/17425250802691074
10. Karelina, T., Demin, O., Zhudenkov, K., Svetlichny, D., Demin, O. Jr., Fairman, D., et al. (2010). Can systems modeling approach be used to understand complex PK-PD relationships? A case study of 5-lipoxygenase inhibition by zileuton. Poster Presented at Annual Meeting of the Population Approach Group in Europe, June 8-11, Berlin.
11. Kuentz, M., Nick, S., Parrott, N., and Rothlisberger, D. (2006). A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur. J. Pharm. Sci. 27, 91-99. doi: 10.1016/j.ejps.2005.08.011
12. Merrimack Pharmaceuticals Inc. (2014). Science [online]. Available at: http://merrimackpharma.com/science[accessed October 13, 2014].
13. Pammolli, F., Magazzini, L., and Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10, 428-438. doi: 10.1038/nrd3405
14. Scannell, J. W., Blanckley, A., Boldon, H., and Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191-200. doi: 10.1038/nrd3681
15. Shoda, L., Kreuwel, H., Gadkar, K., Zheng, Y., Whiting, C., Atkinson, M., et al. (2010). The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse. Clin. Exp. Immunol. 161, 250-267. doi: 10.1111/j.1365-2249.2010.04166.x
16. Sorger, P. K., Allerheiligen, S. R. B., Abernethy, D. R., Altman, R. B., Brouwer, K. L., Califano, A., et al. (2011). Quantitative and Systems Pharmacology in the Post-genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms [online]. Bethesda: National Institutes of Health. Available at: http://www.nigms.nih.gov/news/reports/pages/201110-syspharma.aspx[accessed October 13, 2014].
17. Strougo, A., Eissing, T., Yassen, A., Willmann, S., Danhof, M., and Freijer, J. (2012). First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. J. Pharmacokinet. Pharmacodyn. 39, 195-203. doi: 10.1007/s10928-012-9241-9
18. U.S. Food and Drug Administration. (2013a). Pharmacometrics at FDA [online]. Available at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm167032.htm[accessed October 13, 2014].
19. U.S. Food and Drug Administration. (2013b). Summary of NDA Approvals & Receipts, 1938 to the Present [online]. U.S. Food and Drug Administration. Available at: http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SummaryofNDAApprovalsReceipts1938tothepresent/default.htm[accessed October 13, 2014].
20. Vega-Villa, K., Pluta, R., Lonser, R., and Woo, S. (2013). Quantitative Systems Pharmacology model of NO metabolome and methemoglobin following long-term infusion of sodium nitrite in humans. CPT Pharmacometrics Syst. Pharmacol. 2:e60. doi: 10.1038/psp.2013.35
21. Woltosz, W. S. (2012). If we designed airplanes like we design drugs. J. Comput. Aided Mol. Des. 26, 159-163. doi: 10.1007/s10822-011-9490-5
22. Woodcock, J., and Woosley, R. (2008). The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med. 59, 1-12. doi: 10.1146/annurev.med.59.090506.155819